Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study

Open access
Lee, S.-E., Choi, S. Y., Song, H.-Y., Kim, S.-H., Choi, M.-Y., Park, J. S., Kim, H.-J., Kim, S.-H., Zang, D. Y., Oh, S., Kim, H., Do, Y. R., Kwak, J.-Y., Kim, J.-A., Kim, D.-Y., Mun, Y.-C., Lee, W. S., Chang, M. H., Park, J., Kwon, J. H., Kim, D.-W. · 2016 · Haematologica

Abstract

The aim of the Korean Imatinib Discontinuation Study was to identify predictors for safe and successful imatinib discontinuation. A total of 90 patients with a follow-up of ≥12 months were analyzed. After a median follow-up of 26.6 months after imatinib discontinuation, 37 patients lost the major molecular response. The probability of sustained major molecular response at 12 months and 24 months was 62.2% and 58.5%, respectively. All 37 patients who lost major molecular response were retreated with imatinib therapy for a median of 16.9 months, and all achieved major molecular response again at a median of 3.9 months after resuming imatinib therapy. We observed newly developed or worsened musculoskeletal pain and pruritus in 27 (30%) patients after imatinib discontinuation. Imatinib withdrawal syndrome was associated with a higher probability of sustained major molecular response (P=0.003) and showed a trend for a longer time to major molecular response loss (P=0.098). Positivity (defined as ≥ 17 positive chambers) of digital polymerase chain reaction at screening and longer imatinib duration before imatinib discontinuation were associated with a higher probability of sustained major molecular response. Our data demonstrated that the occurrence of imatinib withdrawal syndrome after imatinib discontinuation and longer duration of imatinib were associated with a lower rate of molecular relapse. In addition, minimal residual leukemia measured by digital polymerase chain reaction had a trend for a higher molecular relapse. (Trial registered at ClinicalTrials.gov: NCT01564836).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2015.139899

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Lee, S.-E., Choi, S. Y., Song, H.-Y., Kim, S.-H., Choi, M.-Y., Park, J. S., Kim, H.-J., Kim, S.-H., Zang, D. Y., Oh, S., Kim, H., Do, Y. R., Kwak, J.-Y., Kim, J.-A., Kim, D.-Y., Mun, Y.-C., Lee, W. S., Chang, M. H., Park, J., Kwon, J. H., & Kim, D.-W.
Venue
Haematologica
Published
2016-02-17
Volume
101
Issue
6
Pages
717-723
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2278657325
Cited by
166
References
2
FWCI
15.54
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. https://app.cochat.ai/papers/10.3324/haematol.2015.139899
The paper
Lee, S.-E., Choi, S. Y., Song, H.-Y., Kim, S.-H., Choi, M.-Y., Park, J. S., Kim, H.-J., Kim, S.-H., Zang, D. Y., Oh, S., Kim, H., Do, Y. R., Kwak, J.-Y., Kim, J.-A., Kim, D.-Y., Mun, Y.-C., Lee, W. S., Chang, M. H., Park, J., . . . Kim, D.-W. (2016). Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. https://doi.org/10.3324/haematol.2015.139899

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.